Tag: congestive heart failure

1. In patients with end-stage heart failure on optimal medical therapy, treatment with a left ventricular assist device (LVAD) significantly reduced the risk of all-cause mortality when compared with medical therapy alone. 2. The difference in mortality was observed at 1 year, while no significant differences were observed at the...
1. In patients with acute myocardial infarction and heart failure/evidence of left ventricular dysfunction, patients treated with valsartan and captopril experienced similar all-cause mortality. 2. Valsartan and captopril were found to be non-inferior with regards to death from cardiovascular causes, recurrent myocardial infarction, and hospitalization for heart failure in this...
Longitudinal assessment of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy protocol Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. While the prognosis associated with this disease has improved, children treated with CNS-directed chemotherapy are at risk of developing neurocognitive deficits. In...
1. Among patients receiving inpatient treatment for decompensated heart failure, an outpatient intervention consisting of pre-discharge education, telephone coaching, and remote monitoring of daily vitals did not reduce readmission rates at 30 or 180 days compared to usual care. There was also no decrease in short-term mortality. 2. The intervention...
1. In patients with heart failure, reduced left ventricular ejection fraction, and prolonged QRS>130 ms, treatment with cardiac resynchronization therapy (CRT), in addition to implantable cardioverter-defibrillator (ICD), significantly reduced the risk of heart failure events when compared with patients only receiving ICD. 2. The rates of device-related complications were similar...
1. Angiotensin-converting-enzyme (ACE) inhibitors had been shown to significantly reduce mortality in patients with heart failure, and it was hypothesized that adding an angiotensin-receptor blocker (ARB) would provide further clinical benefit. 2. The addition of candesartan to ACE inhibitor treatment led to significant reductions in cardiovascular mortality and hospitalization for...
1. In patients with severe heart failure, treatment with enalapril significantly reduced the risk of mortality at 6-months and 1-year when compared with placebo. 2. The reduction in mortality was due to significantly lower risk of mortality resulting from progression of heart failure. 3. Patients on enalapril were significantly more likely...
1. In this randomized controlled trial, heart failure patients randomized to cognitive behavioral therapy (CBT) had decreased depression as compared to usual care, but there was no significant impact on self-care. Evidence Rating Level: 1 (Excellent) Study Rundown: Mental illnesses, such as major depressive disorder, may impact the ability of a...
1. In this study, a high CHA2DS2-VASc score in heart failure patients with or without atrial fibrillation was generally shown to correlate with a high absolute risk of mortality, blood clot, and stroke. 2. However, the CHA2DS2-VASc score demonstrated only moderate accuracy for predicting these endpoints in heart failure patients. Evidence...
Classics Series, Landmark Trials in Medicine
1. In patients with congestive heart failure, the combination of hydralazine and isosorbide dinitrate significantly reduced mortality when compared with placebo. 2. This was one of the first large, randomized trials to demonstrate significant mortality benefit in the treatment of congestive heart failure. Original Date of Publication: June 1986 Study Rundown: Prior...